Malaria: bold decisions needed  by Mullan, Zoë
Editorial
www.thelancet.com/lancetgh   Vol 3   December 2015 e724
Malaria: bold decisions needed
As we went to press this month, the annual meeting of 
the American Society of Tropical Medicine and Hygiene 
(ASTMH) was just wrapping up in Philadelphia. The 
sessions were, as usual, rather malaria-heavy, but this 
year the disease’s predominance was perhaps forgivable 
in light of two key issues.
First was the release, just days before the meeting 
began, of the recommendations of the WHO Strategic 
Advisory Group of Experts on Immunization (SAGE) and 
the Malaria Policy Advisory Committee (MPAC) on use of 
the RTS,S/AS01 malaria vaccine. The groups advised that, 
despite the vaccine having shown partial eﬃ  cacy in a 
large phase 3 trial published in The Lancet in April, further 
real-world demonstration studies should be done before 
wider roll-out. This small bombshell was doubtless on 
many minds at ASTMH as four sets of malaria modelling 
groups presented the results of a major collaborative 
project on the potential public health impact and cost-
eﬀ ectiveness of the vaccine. The study, also published in 
The Lancet, set out to answer questions that the phase 3 
trial was not well positioned to address—ie, on mortality, 
since few deaths were observed in the trial because of 
the uncharacteristically high level of care provided; long-
term impact; and in what settings the vaccine might be 
expected to have most beneﬁ t. 
The models used empirical data on vaccine eﬃ  cacy from 
the phase 3 trial and historical data relating clinical and 
severe incidence to mortality. Over a 15-year follow-up 
period, with 72% coverage of four doses, and at a parasite 
prevalence in 2–10 year olds (ie, transmission intensity) 
of 10–65%, the models predicted that the vaccine could 
prevent a median of 116 480 clinical cases (range across 
models 31 450–160 410) and 484 deaths (189–859) 
per 100 000 fully vaccinated children. The incremental 
cost-eﬀ ectiveness ratio under these assumptions and 
at a vaccine cost of US$5 per dose was estimated to be 
$87 ($48–$244) per disability-adjusted life-year averted, 
making the vaccine highly cost eﬀ ective under the WHO 
threshold of less than gross domestic product per capita. 
When the inevitable question from the ﬂ oor about the 
SAGE/MPAC advice came, WHO’s Vasee Moorthy was 
quick to stress that the organisation had not yet stated 
its formal position on the matter. Peter Smith, chair of 
one of the technical expert groups reporting into MPAC, 
added that the modelling study had shaped the group’s 
thinking, but that uncertainties remained regarding 
implementation practicality and safety (the phase 3 
trial showed a higher number of cases of meningitis and 
cerebral malaria in the vaccine group).
Immunisation, particularly with a partly eﬀ ective 
vaccine, is of course only one component of any malaria 
control strategy. Treatment is also fundamental, and 
worrying signs from western Cambodia were the 
second key issue on the agenda at ASTMH. The region 
is the epicentre of resistance to artemisinins and the 
situation is becoming more and more desperate. With 
the artemisinin combination therapy (ACT) dihydro-
artemisinin–piperaquine “massively failing”, resistance 
spreading into higher transmission areas, and new 
antimalarials more than 4 years away from registration, 
new strategies are urgently needed.
One such strategy is explored in another modelling 
study published in the journal this month. Multiple ﬁ rst-
line therapies (MFT) is a strategy in which several ACTs 
are simultaneously prescribed to individual patients 
in a random manner. The authors’ individual-based 
microsimulation, which accounted for several key 
features not included in previous models, compared 
simultaneous distribution of artemether–lumefan-
trine, artesunate–amodiaquine, and dihydroartemisinin–
piperaquine against strategies in which these ACTs were 
cycled or used sequentially. The model tracked 1 million 
individuals for 20 years, and MFT was found to be 
signiﬁ cantly better at delaying emergence of resistance 
to both artemisinins and their partner drugs. The authors 
suggest adjusting national guidelines accordingly.
Triple therapies (ie, an artemisinin plus two partner 
drugs) are also being considered, and the ongoing 
TRAC II study is exploring the eﬃ  cacy of dihydro arte-
misinin–piperaquine–meﬂ oquine and artemether–lume-
fantrine–amodiaquine against ACTs in eight countries. 
Results are expected at next year’s ASTMH meeting.
WHO now has some monumental decisions to make 
regarding its guidance on both roll-out of the RTS,S 
vaccine and on optimal population-level ACT use. In an 
era in which many talk of elimination, will WHO take the 
bold steps necessary to make this happen?
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